Pricing Log in Create free account
Saturday 17 October 2026 Export BMY’s income statement to Excel — free account

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

59.71 0.86 −1.42%
Market cap
$123.7B
P/E
13.2×
Fwd P/E
11.2×
Dividend yield
4.22%
F-score
8/9
Altman Z
2.14
Beneish M
−2.69
Dividend safety
63/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bristol Myers Squibb Company (BMY) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Bristol Myers Squibb Company (BMY) trades at a EV/Sales of 3.1×. Over the past ten years it has ranged from 2.5× (October 2025) to 7.5× (June 2016); the current reading is higher than 19% of that period. That is below the Drug Manufacturers General industry median of 4.0× and below the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 3.0× (5.85%)
FY2024 3.2× 4.63%
FY2023 3.0× (23.82%)
FY2022 4.0× 11.33%
FY2021 3.6× (12.97%)
FY2020 4.1× (23.60%)
FY2019 5.4× 45.54%
FY2018 3.7× (24.64%)
FY2017 4.9× (4.33%)
FY2016 5.1× (27.42%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 3.0× (6.35%)
Mar 2026 3.3× 8.67%
Dec 2025 3.0× 15.59%
Sep 2025 2.6× (4.88%)
42 more quarters

Against its own ten years

Low 2.5× High 7.5×
Ten-year median 4.0×
Current reading's percentile 20

EV/Sales against peers

Company EV/Sales
SNY Sanofi compare 2.0×
GSK GSK PLC Sponsored ADR compare 2.7×
BMY Bristol Myers Squibb Company 3.1×
PFE Pfizer Inc. compare 3.5×
NVO Novo Nordisk A/S compare 3.6×
AZN AstraZeneca PLC compare 4.6×
NVS Novartis AG compare 5.8×
GILD Gilead Sciences, Inc. compare 7.1×
AMGN Amgen Inc. compare 7.3×
Drug Manufacturers General industry median 4.0×
Healthcare sector median 3.4×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on BMY